Taken together, these findings suggest that targeting the CHK1 checkpoint may serve as a therapeutic strategy to remodel the TME and enhance the response to radiotherapy and ICBs in ARID1A-deficient CRC. The gene discussed is ARID1A; the disease is colorectal carcinoma.